Long-term solutions for the problem of vaccine shortages

Expert Opinion on Biological Therapy

Volumn 4, Issue 6, 2004, Pages 989-992

  Lattanzi, Maria ^a   Rappuoli, Rino ^a  

^a CHIRON VACCINES   (Italy)

Author keywords

Economic development; Intangible value of vaccination; Public and private industry; Public health; Vaccine shortage

Indexed keywords

VACCINE;

DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MANUFACTURE; ECONOMIC ASPECT; REVIEW; VACCINATION;

COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG COSTS; DRUG INDUSTRY; HUMANS; IMMUNIZATION PROGRAMS; PRIVATE SECTOR; RESEARCH; VACCINATION; VACCINES;

EID: 3042590329     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.6.989     Document Type: Review

References (8)

1. RAPPUOLI R, MILLER HI, FALKOW S: The intangible value of vaccination. Science (2002) 297:937-939.
2. RAPPUOLI R: Why must we pay more? New Scientist (2002) 31 August:25.
3. GRÉCO M: The future of vaccines: an industrial perspective. Vaccine (2002) 20:S101-S103.
4. WEBBER D, KREMER M: Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull. World Health Organ. (2001) 79:735-741.
5. WIDDUS R: Public-private partnerships for health: their main targets, their diversity, and their future directions. Bull. World Health Organ. (2001) 79:713-720.
6. MILLER E, SALISBURY D, RAMSAY M: Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in UK: a success story. Vaccine (2002) 20:S58-S67.
7. TROTTER C, EDMUNDS WJ: Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. Br. Med. J. (2002) 324:1-6.
8. WHEELER C, BERKLEY S: Initial lessons from public-private partnerships in drug and vaccine development. Bull. World Health Organ. (2001) 79:728-734.